Novel Insights From a Phase II MEK Inhibitor Trial in BRAF Mutant Melanoma
Journal of Clinical Oncology (JCO) Podcast12/19/12 • 7 min
A discussion of a phase 2 trial of a MEK inhibitor in patients with V600 BRAF mutations and consideration of other relevant results with targeted therapies in this population.
12/19/12 • 7 min
Episode Comments
0.0
out of 5
No ratings yet
Join the conversation
Post
Generate a badge
Get a badge for your website that links back to this episode
Select type & size
<a href="https://goodpods.com/podcasts/journal-of-clinical-oncology-jco-podcast-448/novel-insights-from-a-phase-ii-mek-inhibitor-trial-in-braf-mutant-mela-65956"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to novel insights from a phase ii mek inhibitor trial in braf mutant melanoma on goodpods" style="width: 225px" /> </a>
Copy